3 results  1 of 1 

1 Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
Kyung-Hun Lee, Joohyuk Sohn, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Seock-Ah Im, Sung-Bae Kim
Cancer Res Treat.2021;53(4):1084-1095.   Published online 2021 March 24     DOI: http://dx.doi.org/10.4143/crt.2020.1381
      
2 Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells
Hye-yon Cho, Yong-Beom Kim, Wook-ha Park, Jae Hong No
Cancer Res Treat.2021;53(3):819-828.   Published online 2020 December 16     DOI: http://dx.doi.org/10.4143/crt.2020.1013
      
3 Major clinical research advances in gynecologic cancer in 2012
Dong Hoon Suh, Jae-Weon Kim, Kidong Kim, Hak Jae Kim, Kyung-Hun Lee
J Gynecol Oncol.2013;24(1):66-82.   Published online 2013 January 8     DOI: http://dx.doi.org/10.3802/jgo.2013.24.1.66
      

 1 of 1